Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.
Genetic profiling of endometrial cancers identifies actionable mutations now treatable with approved immunotherapies.
This retrospective NGS study characterizes somatic mutational profiles in an endometrial cancer cohort, identifying actionable molecular alterations and confirming the presence of all four TCGA molecular subtypes in clinical practice. Given the recent approvals of pembrolizumab and lenvatinib based on MMR/MSI status, comprehensive NGS profiling is increasingly essential for optimal endometrial cancer management.
What the study was
- Study design
- Retrospective molecular profiling study
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Mol Cell Oncol
Why it surfaced
Endometrial cancer has seen paradigm-shifting immunotherapy approvals; NGS-based stratification is now clinically standard; Mol Cell Oncol is a peer-reviewed specialty journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.